Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725405 | 0.86 | PARP10 (0.77) | MAPTTDP1L3MBTL1PARP10KMT2A | |
| Hydrochloric Acid SCHEMBL16050040 | 0.84 | PARP10 (0.74) | MAPTTDP1L3MBTL1PARP10KMT2A | |
| SCHEMBL9663679 | 0.84 | PARP10 (0.81) | MAPTTDP1L3MBTL1PARP10KMT2A | |
| SCHEMBL8210174 | 0.84 | MAPT (1.00) | MAPTTDP1L3MBTL1PARP10KMT2A | |
| SCHEMBL9152761 | 0.84 | MAPT (0.81) | MAPTTDP1L3MBTL1PARP10KMT2A | |
| SCHEMBL24157322 | 0.84 | MAPT (0.70) | MAPTTDP1L3MBTL1PARP10KMT2A | |
| SCHEMBL126322 | 0.84 | MAPT (0.81) | MAPTTDP1L3MBTL1PARP10KMT2A | |
| SCHEMBL1192185 | 0.82 | MAPT (0.78) | MAPTTDP1L3MBTL1PARP10KMT2A | |
| SCHEMBL548504 | 0.82 | MAPT (0.78) | MAPTTDP1L3MBTL1PARP10KMT2A | |
| SCHEMBL25863316 | 0.82 | MAPT (0.78) | MAPTTDP1L3MBTL1PARP10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994172-A | Preparation method of poncirtinib phosphate | 广州科锐特生物科技有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-8003628-B2 | Methods of inhibiting osteoclast activity | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003628-B2 | Methods of inhibiting osteoclast activity | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-08-23 | — | — | US | disclosed |
| US-20090306030-A1 | Methods Of Inhibiting Osteoclast Activity | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306030-A1 | Methods Of Inhibiting Osteoclast Activity | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-12-10 | — | — | US | disclosed |
| US-7566741-B2 | Methods of inhibiting osteoclast activity | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566741-B2 | Methods of inhibiting osteoclast activity | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-07-28 | — | — | US | disclosed |
| EP-0513358-B1 | PROCESS FOR PRODUCING CYCLODEXTRIN DERIVATIVE AND POLYMER CONTAINING CYCLODEXTRIN IMMOBILIZED THEREIN | TOPPAN PRINTING CO LTD (JP) | 1997-10-01 | — | — | EP | disclosed |
| EP-0513358-A1 | PROCESS FOR PRODUCING CYCLODEXTRIN DERIVATIVE AND POLYMER CONTAINING CYCLODEXTRIN IMMOBILIZED THEREIN | Toppan Printing Co., Ltd. (JP) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306030-A1 | Methods Of Inhibiting Osteoclast Activity | NFATC1, CD40LG, CD14 | MAPT 4671/4885TDP1 3064/4885L3MBTL1 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.